MetaCap

BriaCell Therapeutics Corp. (BCTX)

NASDAQ: BCTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.06-0.105 (-3.32%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BCTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$26.72M
EPS (TTM)
-$6.97
52-week range
2.60 – 13.09
Day range
3.02 – 3.20
Volume / Avg
109.66K / 250.81K
Beta
—
Next earnings
Dec 10, 2026

52-week range

$2.60$13.09

BCTX stock today

On Nov 20, BCTX ended the session at $3.06, shedding $0.105 (3.32%), versus the S&P 500's 3.70% decline. Trading was light, with 109.66K shares changing hands, about 44% of the average daily volume. Shares are 76.6% below their 52-week high of $13.09, set on Dec 9, 2025 and 17.7% above the 52-week low of $2.60, near the bottom of the past year's range.

BCTX is down 57.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 61.7%. BriaCell Therapeutics has posted a net loss over the last twelve months (EPS of -$6.97), so its P/E ratio is not meaningful. The company is scheduled to report Oct/2026 results on Dec 10.

Summary generated from market data by MetaCap's automated system. Methodology

About BriaCell Therapeutics

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. William V. Williams FCPA, M.D.
Headquarters
West Vancouver, BC

Financial highlights

Full financials

BriaCell Therapeutics reported a net loss of $34.9 million, compared with a loss of $26.3 million a year earlier. Diluted earnings per share came in at -$6.97.

BriaCell Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue—————
Growth—————
Net income$-34.90M$-26.31M$-4.79M$-20.30M$-26.84M
EPS (diluted)$-6.97$-62.19$-43.68$-1.30$-1.73

Earnings

Earnings history
Next report
Dec 10, 2026
Last reported (Jul/2026)
Oct 28, 2026
EPS actual vs est.
$-1.24 vs —

BCTX news

All BCTX news

BriaCell Therapeutics peers

Health Care sector
BCTX peer companies
CompanyPrice% ChgMarket capCompare
TELOTelomir Pharmaceuticals Inc.0.364-17.24%$26.82Mvs BCTX
NSRXNasus Pharma Ltd.2.29-10.20%$26.82Mvs BCTX
EDSAEdesa Biotech Inc.2.00-8.05%$27.02Mvs BCTX
PMNProMIS Neurosciences Inc.3.16-1.56%$28.43Mvs BCTX
AYTUAytu BioPharma Inc.2.660.00%$28.91Mvs BCTX
ATHEAlterity Therapeutics Limited ADR1.52-8.16%$29.02Mvs BCTX
RNTXRein Therapeutics Inc.0.3369-8.38%$29.06Mvs BCTX
NNVCNanoViricides Inc.1.14-2.56%$29.13Mvs BCTX

Indexes, lists and sector

BriaCell Therapeutics stock FAQ

What is BriaCell Therapeutics's stock price today?

BCTX last traded at $3.06 as of Nov 20, 4:00 PM EST, down 3.32% on the day. Prices are delayed at least 15 minutes.

Does BriaCell Therapeutics pay a dividend?

No. BriaCell Therapeutics does not currently pay a regular cash dividend.

When is BriaCell Therapeutics's next earnings date?

BriaCell Therapeutics is expected to report earnings on Thursday, December 10, 2026.

Who is BriaCell Therapeutics's CEO?

Dr. William V. Williams FCPA, M.D. is the chief executive officer of BriaCell Therapeutics Corp..

Has BCTX ever split its stock?

Yes. The most recent BCTX stock split was a 1-for-10 split on Aug 25, 2025, one of 3 splits on record.

What is the BCTX 52-week high?

The 52-week high for BCTX is $13.09 and the 52-week low is $2.60. The stock is currently 76.6% below its high.

Compare BCTX